23 May, 2017
Shares of AstraZeneca plc (LON:AZN) opened at 5147.00 on Tuesday. 4,377,047 shares of the company were exchanged. Henderson Group PLC's holdings in AstraZeneca plc were worth $977,000 as of its most recent filing with the SEC. Looking at this figure it suggests that the shares of AstraZeneca PLC (AZN) may be overvalued, however, this can also depend upon the situation of the market; if the market is strong then it could suggest that AstraZeneca PLC (AZN) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued.
04/05/2017 - Astrazeneca PLC was downgraded to "neutral" by analysts at UBS. First Trust Advisors LP increased its stake in AstraZeneca plc by 2.1% in the first quarter. The rating was maintained by Societe Generale with "Buy" on Thursday, September 10.
11/25/2016 - Astrazeneca PLC was upgraded to "buy" by analysts at Liberum Capital. On Monday, September 28 the stock rating was maintained by Citigroup with "Buy". Institutional investors own 12.90% of the company's stock.
Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on July, 27. The stock had a trading volume of 2,045,742 shares. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.
Stock is now moving with a positive distance from the 200 day simple moving average of approximately 12.75%, and has a solid year to date (YTD) performance of 24.27% which means the stock is constantly adding to its value from the previous fiscal year end price. The firm's market capitalization is GBX 64.71 billion. AstraZeneca plc (LON:AZN) has 0.00% since May 23, 2016 and is. The company had revenue of $5.41 billion for the quarter, compared to analyst estimates of $5.40 billion. AstraZeneca plc had a net margin of 15.21% and a return on equity of 34.30%.
The company reported an impressive total revenue of 23 Billion in the last fiscal year. During the same period in the previous year, the business earned $0.95 EPS. Analysts forecast earnings per share of $0.44, down exactly $0.39 or 46.99 % from 2014's $0.83 EPS. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & global copyright & trademark law. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/05/22/henderson-group-plc-has-977000-position-in-astrazeneca-plc-azn.html.
Several brokerages recently weighed in on AZN. The stock of AstraZeneca plc (LON:AZN) has "Hold" rating given on Wednesday, May 11 by Jefferies. Berenberg Bank decreased their price target on shares of AstraZeneca plc from GBX 5,500 ($71.55) to GBX 5,450 ($70.90) and set a "buy" rating for the company in a report on Tuesday, February 21st. Leerink Swann reaffirmed an "outperform" rating on shares of AstraZeneca plc in a research report on Monday, March 20th. The firm has "Buy" rating given on Wednesday, December 7 by UBS. Berenberg Bank now has a buy rating on the biopharmaceutical company's stock. GBX 4891.69's average target is -4.85% below currents GBX 5141 stock price.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company.